Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about MDGL, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Resmetirom FDA approved Mar 2024 · Rezdiffra |
MASH - Metabolic Dysfunction-Associated Steatohepatitis | Phase 4 · NCT07848191 | Recruiting |
| MGL-3196 | Heterozygous Familial Hypercholesterolemia | Phase 2 · NCT03038022 | Completed |
| Atorvastatin | Healthy | Phase 1 · NCT02749578 | Completed |
| Rosuvastatin | Healthy | Phase 1 · NCT02542969 | Completed |
Also used in these trials (approved or third-party drugs, not MDGL's own candidates): Pioglitazone, Dapagliflozin, Clopidogrel Bisulfate, Simvastatin.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
MDGL holds $961M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MDGL files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| BAKER BROS. ADVISORS LP Director · +1,532 options |
Insider | 2,330,144 | 10.03% | 2026-11-06 |
| JANUS HENDERSON GROUP PLC | Institution (13G, 5%+) | 2,018,647 | 8.69% | 2026-03-31 |
| Paul A Friedman, M.D. | 5%+ holder (13D) | 1,814,831 | 7.81% | 2025-12-10 |
| Rebecca Taub, M.D. | 5%+ holder (13D) | 1,814,831 | 7.81% | 2025-12-10 |
| PAULSON & CO. INC. | Institution (13G, 5%+) | 1,392,188 | 5.99% | 2026-03-31 |
| Rebecca Taub Director · +766 options |
Insider | 1,108,207 | 4.77% | 2026-06-17 |
| Paul A Friedman Director |
Insider | 842,704 | 3.63% | 2026-01-09 |
| William John Sibold President and CEO, Director · +18,743 options |
Insider | 197,746 | 0.85% | 2026-09-09 |
| Richard S Levy Director · +766 options |
Insider | 22,469 | 0.10% | 2026-06-17 |
| Carole Huntsman Chief Commercial Officer · +4,986 options |
Insider | 12,692 | 0.05% | 2026-03-04 |
| Mardi Dier EVP and CFO · +15,699 options |
Insider | 12,490 | 0.05% | 2026-03-04 |
| Shannon T Kelley General Counsel · +5,022 options |
Insider | 10,397 | 0.04% | 2026-11-06 |
Share count 23,229,561 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MDGL and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →